About Us

Overcoming the limitations of potent therapies.

Matinas is an emerging clinical-stage biopharmaceutical company, based in Bedminster, New Jersey. Since commencing operations in 2013, we have been working to develop novel, life-changing pharmaceutical products.

What distinguishes us is our targeted approach to therapeutics. Our technologies and products are strategically designed to overcome the limitations associated with existing therapies. Backed with biopharmaceutical expertise and practical knowledge, we can take highly effective drugs and formulate their delivery to be safer, more efficient, and even more clinically effective, with more impact in improving patients’ lives.

Our company is supported by a world-class team of clinical opinion leaders and critical collaborations with industry-leading firms. We all share an unwavering commitment to research and education in the bioscience community – particularly in the fields of lipids and infectious disease. Moving forward, we will continue to expand the depth and breadth of our disruptive platforms.

Developments in the science of lipids, fungi and bacteria.

Lipid Nano-Crystal Platform

Utilizing lipid-crystal nano-particle cochleates, our LNC platform works to encapsulate existing drugs and resolve significant drug delivery challenges. This technology can help make therapeutics safer, less toxic, more tolerable, and orally bioavailable.

We are advancing the following drug candidates born from our proprietary LNC platform.


An oral encochleated formulation of amphotericin B for treating serious invasive fungal infections (IFIs). Phase 3 registration trial of MAT2203 for treatment of cryptococcal meningitis to commence Q1 2023

Learn More


An oral encochleated formulation of amikacin for the treatment of Non-Tuberculous Mycobacterium (NTM).

Learn More